人福医药：关于重酒石酸去甲肾上腺素注射液获得药品注册证书的公告

Group 1 - The core point of the article is that Yichang Renfu Pharmaceutical Co., Ltd., a subsidiary of Renfu Pharmaceutical, has received the drug registration certificate for heavy tartrate deoxycorticosterone injection from the National Medical Products Administration [2] Group 2 - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu Pharmaceutical Co., Ltd. [2] - The approval of the drug registration certificate indicates a significant regulatory milestone for the company [2] - This development may enhance the company's product portfolio and market position in the pharmaceutical industry [2]